Prexasertib

DB12008InvestigationalSmall molecule

Prexasertib has been used in trials studying the treatment and basic science of mCRPC, Leukemia, Neoplasm, breast cancer, and Ovarian Cancer, among others.

Mechanism: Pharmacologically active on Serine/threonine-protein kinase Chk2 and Serine/threonine-protein kinase Chk1
Curator reviewed
Formula / weight: C₁₈H₁₉N₇O₂ · 365.397 g/mol (avg)
Code names: ACR-368 · LY-2606368

Resolves to

Compound

UNII820NH671E6CAS1234015-52-1ChEMBLCHEMBL3544911PubChem46700756

Structure

InChIKeyDOTGPNHGTYJDEP-UHFFFAOYSA-NSMILESCOC1=CC=CC(OCCCN)=C1C1=CC(NC2=CN=C(C=N2)C#N)=NN1

Targets

O96017CHEK2O14757CHEK1

What you can answer from here — as of July 17, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

20Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Prexasertib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account